CA2493509A1 - Rationally designed polysaccharide lyases derived from chondroitinase b - Google Patents
Rationally designed polysaccharide lyases derived from chondroitinase b Download PDFInfo
- Publication number
- CA2493509A1 CA2493509A1 CA002493509A CA2493509A CA2493509A1 CA 2493509 A1 CA2493509 A1 CA 2493509A1 CA 002493509 A CA002493509 A CA 002493509A CA 2493509 A CA2493509 A CA 2493509A CA 2493509 A1 CA2493509 A1 CA 2493509A1
- Authority
- CA
- Canada
- Prior art keywords
- chondroitinase
- modified
- recombinant
- amino acid
- native
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
The invention relates to rationally designed polysaccharide lyases and uses thereof. In particular, the invention relates to modified chondroitinase B. The modified chondroitinase B enzymes of the invention are useful for a variety of purposes, including cleaving and sequencing polysaccharides such as glycosaminoglycans (GAGs) as well as removing polysaccharides from a solutio n. The invention also includes methods of inhibiting anticoagulant activity, inhibiting angiogenesis, treating cancer, and inhibiting maternal malarial infection.
Claims (35)
1. A modified chondroitinase B having an amino acid sequence of the mature peptide of SEQ ID NO: 2 or conservative substitutions thereof, wherein at least one residue at a position selected from the group consisting of 116, 184, 213, 219, 245, 250, 271, 272, 296, 298, 318, 333, 363 and 364 of SEQ ID NO: 2 has been substituted or deleted.
2. The chondroitinase B of claim 1, wherein the substituted amino acid is a conservative amino acid substitution.
3. The chondroitinase B of claim 1, wherein the chondroitinase B is a substantially purified recombinant form.
4. A modified chondroitinase B having a modified product profile, wherein the modified product profile of the modified chondroitinase B is at least 10%
different than a native product profile of a native chondroitinase B.
different than a native product profile of a native chondroitinase B.
5. The chondroitinase B of claim 4, wherein the modified chondroitinase B has a modified product profile that is at least 50% different than a native product profile of a native chondroitinase B.
6. The chondroitinase B of claim 4, wherein the modified chondroitinase B has a modified product profile that is at least 20% different than a native product profile of a native chondroitinase B.
7. The chondroitinase B of claim 4, wherein the modified chondroitinase B has the amino acid sequence of the mature peptide of SEQ ID NO: 2 wherein at least one amino acid residue has been substituted and wherein the substituted amino acid is at a position selected from the group consisting of 272, 333, and 364 of SEQ ID NO:
2.
2.
8. A modified chondroitinase B having a k cat, or K M value for a substrate that is at least 10% different than a native chondroitinase B k cat or K M value.
9. The chondroitinase B of claim 8, wherein the modified chondroitinase B kcat or KM value is at least 20% different than a native chondroitinase B kcat or KM value.
10. The chondroitinase B of claim 8, wherein the modified chondroitinase B
kcat or KM value is at least 50% different than a native chondroitinase B kcat or KM value.
kcat or KM value is at least 50% different than a native chondroitinase B kcat or KM value.
11. The chondroitinase B of claim 8, wherein the modified chondroitinase B has the amino acid sequence of the mature peptide of SEQ ID NO: 2 wherein at least one amino acid residue has been substituted and wherein the substituted amino acid is at a position selected from the group consisting of 272, 333, 363 and 364 of SEQ ID
NO: 2.
NO: 2.
12. The chondroitinase B of claim 9, wherein the substrate is a glycosaminoglycan.
13. A pharmaceutical preparation comprising a sterile formulation of chondroitinase B of any one of claims 1-12 and a pharmaceutically acceptable carrier.
14. A method of specifically cleaving chondroitin sulfate, comprising:
contacting chondroitin sulfate with the chondroitinase B of any one of claims 12.
contacting chondroitin sulfate with the chondroitinase B of any one of claims 12.
15. A method of specifically cleaving dermatan sulfate, comprising:
contacting dermatan sulfate with the chondroitinase B of any one of claims 1-12.
contacting dermatan sulfate with the chondroitinase B of any one of claims 1-12.
16. The method of claim 14, wherein the method is a method of removing chondroitin sulfate from a chondroitin sulfate containing fluid.
17. The method of claims 15, wherein the method is a method of removing dermatan sulfate from a dermatan sulfate containing fluid.
18. The method of claim 14, wherein the method is a method for sequencing chondroitin sulfate oligosaccharides.
19. The method of claim 15, wherein the method is a method for sequencing dermatan sulfate oligosaccharides.
20. A method of analyzing a sample of polysaccharides, comprising:
contacting the sample with the chondroitinase B of any one of claims 1-12.
contacting the sample with the chondroitinase B of any one of claims 1-12.
21. A method of identifying the presence of a particular polysaccharide in a sample, comprising:
contacting the sample with the chondroitinase B of any one of claims 1-12.
contacting the sample with the chondroitinase B of any one of claims 1-12.
22. A method of determining the purity of sample of polysaccharides, comprising:
contacting the sample with the chondroitinase B of any one of claims 1-12.
contacting the sample with the chondroitinase B of any one of claims 1-12.
23. A method for determining the composition of a sample of polysaccharides, comprising:
contacting the sample with the chondroitinase B of any one of claims 1-12.
contacting the sample with the chondroitinase B of any one of claims 1-12.
24. A method for inhibiting angiogenesis, comprising administering to a subject an effective amount for inhibiting angiogenesis of the chondroitinase B of any one of claims 1-12, or a GAG fragment produced by the chondroitinase B of any one of claims 1-12.
25. The method of claim 24 wherein the chondroitinase B or GAG fragment is administered to a tumor.
26. The method of claim 24, wherein the chondroitinase B or GAG fragment is administered in a biodegradable, biocompatible polymeric delivery device.
27. The method of claim 24, wherein the chondroitinase B or GAG fragment is administered in a pharmaceutically acceptable vehicle for injection.
28. An immobilized modified chondroitinase B comprising:
a modified chondroitinase B as in any one of claims 1-12, and a solid support membrane, wherein the modified chondroitinase B is immobilized on the solid support membrane.
a modified chondroitinase B as in any one of claims 1-12, and a solid support membrane, wherein the modified chondroitinase B is immobilized on the solid support membrane.
29. A method for purifying a recombinant chondroitinase, comprising:
inducing a culture of cells containing a recombinant chondroitinase with an inducing agent for greater than four hours, and isolating the recombinant chondroitinase from the cells to produce a purified chondroitinase.
inducing a culture of cells containing a recombinant chondroitinase with an inducing agent for greater than four hours, and isolating the recombinant chondroitinase from the cells to produce a purified chondroitinase.
30. The method of claim 29, wherein the cells are incubated with the inducing agent at a temperature of between 20° and 26° C.
31. The method of claim 30, wherein the cells are incubated with the inducing agent for at least 8 hours.
32. The method of claims 29, wherein the chondroitinase is selected from the group consisting of chondroitinase AC and B.
33. The method of claim 29, wherein the recombinant chondroitinase includes an terminal Histidine tag.
34. The method of claim 33, further comprising passing the recombinant chondroitinase over a charged Ni 2+ column to isolate the recombinant chondroitinase.
35. A method for isolating a recombinant chondroitinase, comprising:
lysing a cell culture containing a recombinant chondroitinase having a terminal Histidine tag, and passing the recombinant chondroitinase over a charged Ni 2+ column to isolate the recombinant chondroitinase.
lysing a cell culture containing a recombinant chondroitinase having a terminal Histidine tag, and passing the recombinant chondroitinase over a charged Ni 2+ column to isolate the recombinant chondroitinase.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38550902P | 2002-06-03 | 2002-06-03 | |
US60/385,509 | 2002-06-03 | ||
PCT/US2003/017680 WO2003102160A2 (en) | 2002-06-03 | 2003-06-03 | Rationally designed polysaccharide lyases derived from chondroitinase b |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2493509A1 true CA2493509A1 (en) | 2003-12-11 |
CA2493509C CA2493509C (en) | 2010-03-09 |
Family
ID=29712183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002493509A Expired - Fee Related CA2493509C (en) | 2002-06-03 | 2003-06-03 | Rationally designed polysaccharide lyases derived from chondroitinase b |
Country Status (7)
Country | Link |
---|---|
US (4) | US6962699B2 (en) |
EP (1) | EP1532241B1 (en) |
AT (1) | ATE481478T1 (en) |
AU (1) | AU2003243396A1 (en) |
CA (1) | CA2493509C (en) |
DE (1) | DE60334220D1 (en) |
WO (1) | WO2003102160A2 (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003527822A (en) | 1998-08-27 | 2003-09-24 | マサチューセッツ インスティテュート オブ テクノロジー | Rationally designed heparinases from heparinases I and II |
WO2000033764A1 (en) * | 1998-12-04 | 2000-06-15 | Pathak Chandrashekhar P | Biocompatible crosslinked polymers |
CA2370539C (en) | 1999-04-23 | 2009-01-06 | Massachusetts Institute Of Technology | System and method for notating polymers |
JP2003525946A (en) * | 2000-03-08 | 2003-09-02 | マサチューセッツ インスティテュート オブ テクノロジー | Heparinase III and uses thereof |
CA2422059C (en) | 2000-09-12 | 2012-05-15 | Massachusetts Institute Of Technology | Methods and products related to low molecular weight heparin |
CA2423469A1 (en) | 2000-10-18 | 2002-04-25 | Massachusetts Institute Of Technology | Methods and products related to pulmonary delivery of polysaccharides |
CA2484604C (en) * | 2002-05-03 | 2011-08-02 | Massachusetts Institute Of Technology | .delta. 4,5 glycuronidase and uses thereof |
US8183350B2 (en) | 2002-05-04 | 2012-05-22 | Acorda Therapeutics, Inc. | Compositions and methods for promoting neuronal outgrowth |
CA2486456C (en) * | 2002-05-20 | 2012-07-17 | Massachusetts Institute Of Technology | Method for sequence determination using nmr |
ATE481478T1 (en) * | 2002-06-03 | 2010-10-15 | Massachusetts Inst Technology | RATIONALLY DESIGNED LYASES DERIVED FROM CHONDROITINASE B |
ATE508197T1 (en) * | 2002-08-15 | 2011-05-15 | Acorda Therapeutics Inc | CHIMERIC PROTEIN |
JP4606712B2 (en) * | 2003-01-08 | 2011-01-05 | マサチューセッツ インスティテュート オブ テクノロジー | 2-O sulfatase compositions and related methods |
AU2016204464B2 (en) * | 2003-05-16 | 2018-03-22 | Acorda Therapeutics, Inc. | Proteoglycan degrading mutants for treatment of cns |
EP2353606B1 (en) * | 2003-05-16 | 2013-04-17 | Acorda Therapeutics, Inc. | Compositions and methods for the treatment of CNS injuries |
CA2525784C (en) | 2003-05-16 | 2019-04-09 | Acorda Therapeutics, Inc. | Proteoglycan degrading mutants for treatment of cns |
US7959914B2 (en) | 2003-05-16 | 2011-06-14 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
WO2005000219A2 (en) * | 2003-05-28 | 2005-01-06 | The Board Of Trustees Of The University Of Illinois | Composition for blocking hiv binding to dendritic cells and methods of use thereof |
US7507570B2 (en) * | 2004-03-10 | 2009-03-24 | Massachusetts Institute Of Technology | Recombinant chondroitinase ABC I and uses thereof |
WO2005111627A2 (en) * | 2004-04-15 | 2005-11-24 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
WO2005110438A2 (en) * | 2004-04-15 | 2005-11-24 | Massachusetts Institute Of Technology | Methods and products related to the intracellular delivery of polysaccharides |
US20060127950A1 (en) * | 2004-04-15 | 2006-06-15 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
CA2566731C (en) | 2004-05-18 | 2012-07-24 | Acorda Therapeutics, Inc. | Methods of purifying chondroitinase and stable formulations thereof |
CA2614068A1 (en) * | 2004-06-29 | 2006-08-24 | Massachusetts Institute Of Technology | Methods and compositions related to the modulation of intercellular junctions |
WO2006083328A2 (en) * | 2004-09-15 | 2006-08-10 | Massachusetts Institute Of Technology | Biologically active surfaces and methods of their use |
US7485295B2 (en) | 2005-09-26 | 2009-02-03 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
EP2008096A2 (en) * | 2006-04-03 | 2008-12-31 | Massachusetts Institute of Technology | Glycomic patterns for the detection of disease |
US7722864B2 (en) | 2006-10-10 | 2010-05-25 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
AU2008205410B2 (en) | 2007-01-05 | 2013-10-10 | Massachusetts Institute Of Technology | Compositions of and methods of using sulfatases from flavobacterium heparinum |
WO2009025888A2 (en) | 2007-05-10 | 2009-02-26 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety |
GB0712302D0 (en) * | 2007-06-22 | 2007-08-01 | Cambridge Entpr Ltd | Chrondroitinase polypeptides |
US20090286289A1 (en) * | 2008-03-10 | 2009-11-19 | Pang Danny Z | Production of Hyaluronate Unsaturated Disaccharides and its Application |
US9045742B2 (en) * | 2009-05-29 | 2015-06-02 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant Edwardsiella bacterium |
US9796970B1 (en) | 2017-04-24 | 2017-10-24 | Advantek Serum Laboratories Ltd. | Production of high purity chondroitinase ABC |
CN111593040B (en) * | 2020-06-20 | 2022-08-30 | 山东大学 | Dermatan sulfate lyase and application thereof |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US122793A (en) * | 1872-01-16 | Improvement in air-supplying attachments for stoves | ||
US99628A (en) * | 1870-02-08 | Signors to themselves and a | ||
US197933A (en) * | 1877-12-11 | Improvement in wood-screws | ||
US92037A (en) * | 1869-06-29 | Improved shoe-pegging- machine | ||
US204869A (en) * | 1878-06-11 | Improvement in weighing-scales | ||
US128225A (en) * | 1872-06-25 | Improvement in workmen s time-registers | ||
US91472A (en) * | 1869-06-15 | Improvement in plows | ||
US37376A (en) * | 1863-01-06 | Improvement in breech-loading fire-arms | ||
US169143A (en) * | 1875-10-26 | Improvement in perforating stamps | ||
US91471A (en) * | 1869-06-15 | steigmeyer | ||
US191587A (en) * | 1877-06-05 | Improvement in piano-forte bridges | ||
US8820A (en) * | 1852-03-23 | Improvement in friction-primers for cannon | ||
JPS6031478B2 (en) | 1978-02-10 | 1985-07-22 | 生化学工業株式会社 | Method for producing pure chondroitinase B |
US4341869A (en) | 1980-08-25 | 1982-07-27 | Massachusetts Institute Of Technology | Process for producing heparinase |
US5169772A (en) | 1988-06-06 | 1992-12-08 | Massachusetts Institute Of Technology | Large scale method for purification of high purity heparinase from flavobacterium heparinum |
JP2726275B2 (en) | 1988-08-24 | 1998-03-11 | 生化学工業株式会社 | Purification of glycosaminoglycan degrading enzyme |
JPH0693836B2 (en) | 1988-11-25 | 1994-11-24 | 新技術事業団 | Heparinase-producing microorganism belonging to the genus Bacillus, novel heparinase, and method for producing the same |
ZA912770B (en) | 1990-04-16 | 1992-01-29 | Bethesda Eye Inst | Enzymatic disinsertion of vitreous body |
JPH04270327A (en) | 1991-02-26 | 1992-09-25 | Fuji Photo Optical Co Ltd | Exposure correcting device for camera |
JP3110064B2 (en) | 1991-03-06 | 2000-11-20 | 生化学工業株式会社 | Novel heparitinase, method for producing the same and bacteria producing the same |
US5262325A (en) | 1991-04-04 | 1993-11-16 | Ibex Technologies, Inc. | Method for the enzymatic neutralization of heparin |
US5668274A (en) | 1991-04-23 | 1997-09-16 | Akzo Nobel N.V. | Sulfated glycosaminoglycanoid derivatives of the dermatan sulfate and chondroitin sulfate type |
US5714376A (en) | 1991-10-23 | 1998-02-03 | Massachusetts Institute Of Technology | Heparinase gene from flavobacterium heparinum |
US6001630A (en) | 1992-06-26 | 1999-12-14 | Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) | Pharmaceutical compositions of chondroitinase ABC isolated from Proteus vulgaris ATCC 6896 |
US5496718A (en) | 1992-06-26 | 1996-03-05 | Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) | Chondroitinase ABC isolated from proteus vulgaris ATCC 6896 |
US5773277A (en) | 1992-06-26 | 1998-06-30 | Seikagaku Kogyo Kabushiki Kaisha | Crystalline chondroitinase isolated from Proteus vulgaris ATCC 6896 |
JP3419811B2 (en) | 1993-02-24 | 2003-06-23 | マルハ株式会社 | Chondroitinase gene |
US5389539A (en) | 1992-11-30 | 1995-02-14 | Massachusetts Institute Of Technology | Purification of heparinase I, II, and III from Flavobacterium heparinum |
US5578480A (en) | 1993-04-23 | 1996-11-26 | American Cyanamid Company | Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris |
US5801162A (en) | 1993-09-30 | 1998-09-01 | Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) | Dermatan sulfate compositions and antithrombotic compositions containing same |
WO1995013830A1 (en) | 1993-11-17 | 1995-05-26 | Massachusetts Institute Of Technology | Method for inhibiting angiogenesis using heparinase |
US5525500A (en) | 1994-04-22 | 1996-06-11 | American Cyanamid Company | Chromatographic process for the copurification of chondroitinase I and II proteins from Proteus vulgaris |
US5498536A (en) | 1994-04-22 | 1996-03-12 | American Cyanamid Company | Chondroitinase II from Proteus vulgaris |
EP0756636A4 (en) | 1994-04-22 | 1997-12-17 | American Cyanamid Co | Chondroitinases i and ii, methods of preparation, and use thereof |
US5681733A (en) | 1994-06-10 | 1997-10-28 | Ibex Technologies | Nucleic acid sequences and expression systems for heparinase II and heparinase III derived from Flavobacterium heparinum |
US5619421A (en) | 1994-06-17 | 1997-04-08 | Massachusetts Institute Of Technology | Computer-implemented process and computer system for estimating the three-dimensional shape of a ring-shaped molecule and of a portion of a molecule containing a ring-shaped structure |
US5997863A (en) | 1994-07-08 | 1999-12-07 | Ibex Technologies R And D, Inc. | Attenuation of wound healing processes |
US6093563A (en) * | 1994-07-08 | 2000-07-25 | Ibex Technologies R And D, Inc. | Chondroitin lyase enzymes |
US5965507A (en) | 1995-06-08 | 1999-10-12 | Procter & Gamble Company | Cleaning compositions comprising chondroitinase |
WO1997016556A1 (en) | 1995-10-30 | 1997-05-09 | Massachusetts Institute Of Technology | Rationally designed polysaccharide lyases derived from heparinase i |
US5866120A (en) | 1995-11-22 | 1999-02-02 | Advanced Corneal Systems, Inc. | Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase |
IT1285546B1 (en) | 1996-01-16 | 1998-06-18 | Alfa Wassermann Spa | USE OF LOW MOLECULAR WEIGHT DERMATANE SULFATE AND MEDICINAL SPECIALTIES THAT CONTAIN IT IN THE THERAPY AND PREVENTION OF |
DE69829605T2 (en) | 1997-05-02 | 2006-02-09 | Seikagaku Corp. | Chondroitinase-containing compositions |
EP0900569B1 (en) | 1997-08-22 | 2002-10-02 | Seikagaku Corporation | Therapeutic agent for herniated intervertebral disc |
US6190875B1 (en) | 1997-09-02 | 2001-02-20 | Insight Strategy & Marketing Ltd. | Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe |
US5968822A (en) | 1997-09-02 | 1999-10-19 | Pecker; Iris | Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells |
US6378527B1 (en) | 1998-04-08 | 2002-04-30 | Chondros, Inc. | Cell-culture and polymer constructs |
WO1999058650A1 (en) | 1998-05-13 | 1999-11-18 | Biomarin Pharmaceuticals | Lytic enzymes useful for treating fungal infections |
JP2000044601A (en) | 1998-07-29 | 2000-02-15 | Seikagaku Kogyo Co Ltd | New galactosaminoglucan |
CA2370539C (en) | 1999-04-23 | 2009-01-06 | Massachusetts Institute Of Technology | System and method for notating polymers |
WO2001034781A2 (en) | 1999-11-12 | 2001-05-17 | Biomarin Pharmaceuticals | Lytic enzymes useful for treating fungal infections |
ATE413886T1 (en) | 1999-11-17 | 2008-11-15 | Biomarin Pharm Inc | REDUCING ANGIOGENESIS USING CHONDROITIN SULPHATE DEGRADING ENZYMES |
WO2001038399A1 (en) | 1999-11-24 | 2001-05-31 | Seikagaku Corporation | Method of treating surface tissue diseases |
WO2001039795A2 (en) | 1999-12-02 | 2001-06-07 | Ibex Technologies, Inc. | Attenuation of fibroblast proliferation |
WO2001053474A2 (en) | 2000-01-21 | 2001-07-26 | Ibex Pharmaceuticals, Inc. | Flavobacterium heparinum expression system |
JP2003525946A (en) | 2000-03-08 | 2003-09-02 | マサチューセッツ インスティテュート オブ テクノロジー | Heparinase III and uses thereof |
CA2422059C (en) | 2000-09-12 | 2012-05-15 | Massachusetts Institute Of Technology | Methods and products related to low molecular weight heparin |
CA2423469A1 (en) | 2000-10-18 | 2002-04-25 | Massachusetts Institute Of Technology | Methods and products related to pulmonary delivery of polysaccharides |
US20030008820A1 (en) | 2001-03-27 | 2003-01-09 | Massachusetts Institute Of Technology | Methods and products related to FGF dimerization |
US20030096281A1 (en) | 2001-09-14 | 2003-05-22 | Ganesh Venkataraman | Methods of making glycomolecules with enhanced activities and uses thereof |
US20040214228A9 (en) | 2001-09-14 | 2004-10-28 | Ganesh Venkataraman | Methods of evaluating glycomolecules for enhanced activities |
GB0205022D0 (en) | 2002-03-04 | 2002-04-17 | Univ Cambridge Tech | Materials and methods for the treatment of cns damage |
EP1518120A4 (en) | 2002-03-11 | 2008-08-13 | Momenta Pharmaceuticals Inc | Analysis of sulfated polysaccharides |
EP1551852A4 (en) | 2002-04-25 | 2007-03-21 | Momenta Pharmaceuticals Inc | Methods and products for mucosal delivery |
CA2484604C (en) | 2002-05-03 | 2011-08-02 | Massachusetts Institute Of Technology | .delta. 4,5 glycuronidase and uses thereof |
CA2486456C (en) | 2002-05-20 | 2012-07-17 | Massachusetts Institute Of Technology | Method for sequence determination using nmr |
ATE481478T1 (en) | 2002-06-03 | 2010-10-15 | Massachusetts Inst Technology | RATIONALLY DESIGNED LYASES DERIVED FROM CHONDROITINASE B |
EP1587408A4 (en) | 2002-12-20 | 2007-09-05 | Momenta Pharmaceuticals Inc | Glycan markers for diagnosing and monitoring disease |
JP4606712B2 (en) | 2003-01-08 | 2011-01-05 | マサチューセッツ インスティテュート オブ テクノロジー | 2-O sulfatase compositions and related methods |
KR100846449B1 (en) * | 2003-03-27 | 2008-07-16 | 삼성전자주식회사 | Method for setting web camera mode of mobile composition device |
CA2525784C (en) | 2003-05-16 | 2019-04-09 | Acorda Therapeutics, Inc. | Proteoglycan degrading mutants for treatment of cns |
US7407810B2 (en) | 2003-09-04 | 2008-08-05 | Momenta Pharmaceuticals, Inc. | Methods and apparatus for characterizing polymeric mixtures |
US7851223B2 (en) | 2004-02-27 | 2010-12-14 | Roar Holding Llc | Method to detect emphysema |
WO2005084710A2 (en) | 2004-03-02 | 2005-09-15 | Massachusetts Institute Of Technology | Nanocell drug delivery system |
CA2566731C (en) | 2004-05-18 | 2012-07-24 | Acorda Therapeutics, Inc. | Methods of purifying chondroitinase and stable formulations thereof |
-
2003
- 2003-06-03 AT AT03756399T patent/ATE481478T1/en not_active IP Right Cessation
- 2003-06-03 CA CA002493509A patent/CA2493509C/en not_active Expired - Fee Related
- 2003-06-03 DE DE60334220T patent/DE60334220D1/en not_active Expired - Lifetime
- 2003-06-03 US US10/454,816 patent/US6962699B2/en not_active Expired - Lifetime
- 2003-06-03 EP EP03756399A patent/EP1532241B1/en not_active Expired - Lifetime
- 2003-06-03 AU AU2003243396A patent/AU2003243396A1/en not_active Abandoned
- 2003-06-03 WO PCT/US2003/017680 patent/WO2003102160A2/en not_active Application Discontinuation
-
2004
- 2004-10-14 US US10/966,671 patent/US7129335B2/en not_active Expired - Lifetime
- 2004-10-14 US US10/967,041 patent/US7105334B2/en not_active Expired - Lifetime
-
2006
- 2006-09-08 US US11/518,389 patent/US20070065424A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1532241B1 (en) | 2010-09-15 |
US20050227320A1 (en) | 2005-10-13 |
DE60334220D1 (en) | 2010-10-28 |
EP1532241A2 (en) | 2005-05-25 |
US20050233419A1 (en) | 2005-10-20 |
CA2493509C (en) | 2010-03-09 |
AU2003243396A8 (en) | 2003-12-19 |
WO2003102160A3 (en) | 2004-09-16 |
US20070065424A1 (en) | 2007-03-22 |
EP1532241A4 (en) | 2005-12-14 |
US20040091472A1 (en) | 2004-05-13 |
AU2003243396A1 (en) | 2003-12-19 |
US7129335B2 (en) | 2006-10-31 |
ATE481478T1 (en) | 2010-10-15 |
US6962699B2 (en) | 2005-11-08 |
WO2003102160A2 (en) | 2003-12-11 |
US7105334B2 (en) | 2006-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2493509A1 (en) | Rationally designed polysaccharide lyases derived from chondroitinase b | |
JP5957096B2 (en) | Bacillus, hyaluronic acid enzyme and use thereof | |
Wong et al. | Alginate lyase: review of major sources and enzyme characteristics, structure-function analysis, biological roles, and applications | |
EP0487627B1 (en) | Wound healing preparations containing heparanase | |
EP4015627B1 (en) | Clostridium histolyticum enzyme | |
US9956273B2 (en) | Compositions and methods for promoting neuronal outgrowth | |
CA2558984A1 (en) | Recombinant chondroitinase abc i and uses thereof | |
JP2006504437A5 (en) | ||
JP2004208684A5 (en) | ||
CN107312765B (en) | Glycosaminoglycan lyase and coding gene and application thereof | |
CN112126606B (en) | Photobacterium QA16 and culture method and application thereof | |
CN115521373B (en) | Triple helix recombinant humanized type I collagen, preparation method and application thereof | |
Kale et al. | Chondroitin lyase from a marine Arthrobacter sp. MAT3885 for the production of chondroitin sulfate disaccharides | |
CN109628347B (en) | Photobacterium FC615 and culture method and application thereof | |
Sindelar et al. | Hyaluronidases and hyaluronate lyases: From humans to bacteriophages | |
CN103923899B (en) | A kind of glycosaminoglycan lyases and encoding gene and application | |
RU2295538C2 (en) | Method for preparing heparins of low molecular mass | |
Stevens | Secretory granule proteoglycans of mast cells and natural killer cells | |
Pang et al. | Enzymatic production of low-molecular-weight hyaluronan and its oligosaccharides: A review and prospects | |
Watson et al. | Characterization of a factor required for the differentiation of myeloid and lymphoid cells in vitro | |
Ennamany et al. | SECMA 1®, a mitogenic hexapeptide from Ulva algeae modulates the production of proteoglycans and glycosaminoglycans in human foreskin fibroblast | |
CN111481660B (en) | Pharmaceutical composition containing depolymerizing enzyme with function of degrading extracellular polymers of klebsiella pneumoniae | |
ES2617181T3 (en) | Porphranases and their use to hydrolyze polysaccharides | |
WO2012136768A1 (en) | Use of mutants of human hyaluronidase ph-20 with increased chondroitinase activity for axonal regrowth | |
EP1616955A1 (en) | Catalyst for sugar chain cleavage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20210603 |